

Date: _____
DEPRESSIVE DISORDERS

Core Features (GMI)

1. ↓ Energy
2. ↓ Mood
3. ↓ Interest (Anhedonia: loss of pleasure from formerly previously pleasurable activities).

Other Important Features (DIGEST-CAPS)

- ① Depressed Affect / Mood (A)
- ② ↓ Interest (Anhedonia) (A)
- ③ Pathological Guilt (NK)
- ④ ↓ Energy (Fatigue) (V)
- ⑤ Sleep problems → Early Morning Awakening (V)
Terminal Insomnia (V)
- ⑥ ↓ Concentration (NK)
- ⑦ Appetite Changes (↓ Intake, loss of taste, significant weight loss) (V)
- ⑧ Psychomotor Changes (retardation/acceleration)
- ⑨ Suicidal behaviour (NK)

NOTE:

DIAGNOSIS

5 out of 9 symptoms with at least 2 core symptoms are persistent & pervasive for > 2 weeks


NOTE:

Initial Insomnia → Anxiety

Terminal Insomnia → Depression

NOTE: Significant weight loss
 5% Body Weight in 1 month


OBJECTIVE SIGNS
of Depression



	OMEGA SIGN	VERAGUTH SIGN	
Described by	Charles Darwin	Otto Veraguth	Sign (patient appears to stare)
Appearance	Ω shaped folds at the root of nose	Triangular/diagonal folds in upper eyelid	
Due to contraction of	Corrugator & browens muscle	Palpebral Muscle	

In Veraguth sign → patient appears to stare

Severity of Depression



	Mild	Moderate	Severe
Symptoms of Depression	Less Prominent	Prominent	Very Prominent
Vegetative Symptoms (Affects sleep & appetite)	Absent	Present	Present
Mood Congruent Psychotic Symptom (eg: Nihilistic delusion)	Absent	may be present	may be present
Functionality	Normal	Normal	Affected

COTARD SYNDROME

- ① Nihilistic Delusion (Delusion of negation, eg: person believes body part is absent) +
- ② Severe Depression

Date: _____

Types of Depression

I Based on Number of Episodes

Single episode depression

Recurrent
depressive disorders (ICD)
Major Depressive
disorders (MDD) (DSM)
Unipolar Depression

≥ 2 episodes of depression
(including current episode)

II

NOTE: ICD Classification of Single Episode

- ① Mild Severity
- ② Moderate without psychotic symptoms
- ③ Severe without psychotic symptoms
- ④ Moderate with psychotic symptoms
- ⑤ Severe with psychotic symptoms
- ⑥ In partial remission
- ⑦ In full remission
- ⑧ Other specified single episode depressive disorders
- ⑨ Unspecified single episode depressive disorders


III Special Types

① Pre-menstrual Dysphoric Disorder (PMDD)
aka: Pre-menstrual Syndrome / Symptoms (PMS)


- Depressive symptoms before onset of menstrual cycle & resolves after onset of menstrual cycle.

• Risk Factor for depression if recurrent

Rx: SSRIs if necessary.



② Seasonal Affective Disorder (SAD)



- Depressive episodes during winters with NO OTHER TRIGGERS.

Rx


- ① Light Therapy / Phototherapy (Specific Treatment of Choice)
- ② Antidepressants

③ Persistent Mood disorders

A) Dysthymia


- Chronic low mood persisting for ≥ 2 years

ex: in cancer patients with long term medical comorbidities




B) Cyclothymia

- Cyclical low & high moods for ≥ 2 years




C) Double Depression (MCQ)

- Depression developing in a patient with dysthymia.
- Bad prognosis \rightarrow due to resistance to treatment.



d) Chronic Major Depression (CMD)

↳ Major depressive disorder (MDD) ≥ 2 years




e) Atypical Depression

Features:

- ① Hyperomnia
- ② Hyperphagia (Carbohydrate Craving)
↳ Weight gain & Obesity
- ③ \uparrow Interpersonal Sensitivity (become very sensitive to criticism)

~~④~~

Date: _____
Double Depression




- ④ Paradoxical reactivity (e.g. depressed but laughs at jokes)
- ⑤ Leaden paralysis (feeling of heaviness / paralysis of body parts) **(MCQ)**

- R
- ① SSRIs preferred
 - ② MAOIs

Note: Avoid TCAs in atypical depression
(MCQ)

ETIOPATHOGENESIS & EPIDEMIOLOGY

Aetiopathogenesis




NOTE: (MCQ)

↓ S-HIA in individual who are suicidal

BIOPSYCHOSOCIAL MODEL

Depression is multifactorial.



EPIDEMIOLOGY

1. Mental Illnesses → 2nd highest disease burden
↳ 15%

2. Depression → MC mental illness
↳ most burdensome

3. 5-15% population → have at least 1 episode of depression

4. Risk of Recurrence in depression:
- ① After 1 episode → 50%
 - ② After 2 episodes → 70%
 - ③ After 3 or more episodes → 90%


4. Chronic Condition (episodes can last between 6 months to 1.5 years)

5. Resistant depression → 10-20% cases

NOTE:

- ① Most burdensome illness: CARDIOVASCULAR DISEASE
- ② 15% cases with mood disorders succumb to suicide

TREATMENT



- I Pharmacological Interventions (ANTI-DEPRESSANTS)
- Choice of drug depends on:
- ① Required therapeutic effects
 - ② Tolerable Side Effects
 - ③ Drugs that have worked in the past for a patient.

A) SSRI (selective Serotonin Receptor Inhibitor)

MOA: Inhibit SHT Transporter (SERT)
on pre-synaptic membrane

↓
prevents reuptake

↓
↑ Concentration of serotonin at the synapse

↙ Immediate Action

Side Effects

↘ 2-3 weeks


↓
Downregulation of Pre-synaptic receptors

↓
Improvement of symptoms

Side Effects

→ Avoided by gradually increasing the dose

- ① GI disturbances (MC): N/V/GI distress
- ② Sleep disturbances: Insomnia/Sedation/
Vivid dreams/nightmares
- ③ Sexual dysfunction (↑ S-HT): Anorexia, ↓
libido/erectile dysfunction/delayed
ejaculation
- ④ ↑ Sweating
- ⑤ Ulcer/ GI pain



B) SNRI (Serotonin & Norepinephrine Receptor Intake)

MoA → Dual-acting antidepressants → ↑ S-HT
↳ ↑ NE

• Efficacy: similar to SSRIs.

- Drugs: ① Duloxetine ② Venlafaxine
③ Milnacipran

Date: _____
Anti-depressants with decreased sexual side effects

① least sexual side effects: BUPROPION

MoA → ↑ dopamine, ↑ norepinephrine
↳ no ↑ in 5HT

Other Uses → Misture antiwringing agent

Other Advantage → least weight gain

Side Effects

- a) ↑ Anxiety
- b) Insomnia
- c) Dreams
- d) ↓ Seizure threshold (v/o v/o seizures).

20
OTHER DRUGS with less Sexual

① Mirtazepine
↳ S/E: Sedation, Weight Gain,
Apremilocypion

25
② Trazadone
↳ S/E: Parosmia (MCO)

③ Axoxmelatine

↳ Acts on M₁/M₂ receptors
+ Serotonin receptors

④ ~~Vilazodone~~, Vilazodone → SHT_{2A} partial agonist

⑤ Vortioxetine (MCO)

↳ New multi-modal serotoninergic agent

MoA

- SHT transport blocker
- SHT_{1A} agonist
- SHT_{1B} partial agonist
- SHT_{1D} antagonist
- SHT₃ antagonist
- SHT_{2A} antagonist → PROCOGNITIVE EFFECT

↓
↑ Working Memory,
Attention & Focus

Duration of treatment

9 months - 12 months

↓ NO RE LAPSES

Taper & stop medication

Withdrawal Symptoms

- Seen upon abrupt stoppage

Least Withdrawal Symptoms (MCQ)

↓
Fluoxetine (long $t_{1/2}$ with active metabolites)

Most Withdrawal Symptoms (MCQ)

↓
Paroxetine (very short $t_{1/2}$)

Withdrawal Symptoms

↓

Physical
Irritable
Moody
Body aches
Headaches
Nausea

↓

Sensory
Itching
Tingling
Numbness

• Withdrawal symptoms usually spontaneously resolve in 7-10 days

Date _____
TREATMENT OF RESISTANT DEPRESSION

(10-10%)


I. Augmentation Strategies

1. Augmentation works by combining anti-depressants with different mechanisms of action

(OR)

① AD₁ + AD₂
② AD +

2. Combine Anti-depressants with low dose of:



3. Combine with Electroconvulsive Therapy

4. Combine with Light Therapy

5. Combine with Ketamine (Nasal form: Esketamine)

25 AUGMENTATION

- ① AD₁ + AD₂
- ② AD + low-dose → FA
- ③ AD + ECT → anti-Psychotic
- ④ AD + ~~Light Therapy~~ → ↑
- ⑤ AD + Esketamine → Li

POST-PARTUM DISORDERS

Post-partum period:

- ① DSM → 4 weeks
- ② ICD → 6 weeks
- ③ Clinically → 6 months

	POST-PARTUM BLUES (BABY BLUES)	POST PARTUM PSYCHOSIS	POST PARTUM DEPRESSION
Timing (After delivery)	Occurs & resolves within <u>2 weeks</u> Lasts for a <u>few days</u>	• <u>Abrupt Onset</u> • <u>Prominent</u> within <u>48-72 hrs</u> • Occurs around <u>2 weeks post-partum</u>	Onset <u>> 2 weeks</u> (After 1 week)
Prevalence	50-80% of post partum women	1 in 1000 pregnancies (Rare)	5-15% of post partum women
Features	• Self-limiting • Lasts for few weeks days	• Psychotic symptoms <u>+ve</u> • <u>Losses DANGER to baby self</u>	Symptoms of Depression (DSM 5 / ICD 10)
Treatment	Conservative Management	• Antipsychotics • Mood Mediators	<u>SERTALINE</u> (preferred SSRI)

NOTE: SSRI's to be avoided in pregnant & lactating women

- ① Paroxetine
- ② Fluoxetine

Note:

FDA-approved Neurosteroids for Post-partum Depression (PPD)

- ① Brexinalone } → Allopregalone
- ② Zexonalone } enaloxmes

PSYCHOLOGICAL INTERVENTIONS IN DEPRESSION

1. Solution Focused therapy: Shift focus from thoughts to actions

2. Interpersonal Psychotherapy (IPT)

Goals

- ① Effective Communication
 - ② ↑ Help seeking behaviour
 - ③ ↑ Safety Net
- } ↓ feeling of helplessness & ↑ support

3. Cognitive Behaviour Therapy (CBT)